logo
Plus   Neg
Share
Email

Otonomy Inc. (OTIC) Is Rising On Phase 3 Study Results

Otonomy Inc. (OTIC) announced after the bell Wednesday that its Phase 3 trial of OTIVIDEX in patients with Ménière's disease achieved its primary efficacy endpoint. The stock is now up 2.75 on 2.7 million shares.

Otonomy moved in a narrow range throughout Wednesday's session and closed down by 0.05 at $2.80.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT